Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Danone    BN   FR0000120644

DANONE

(BN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Danone decides on Mead Johnson as takeover target - sources

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/17/2014 | 02:52pm EDT
Yoghurt produced by French Dairy Group Danone are displayed on a shelf in an supermarket in Lanton

PARIS (Reuters) - French food giant Danone (>> DANONE), maker of Activia yoghurt and Evian water, has decided it wants to pursue a takeover of U.S. infant formula maker Mead Johnson Nutrition Group (>> Mead Johnson Nutrition CO), sources familiar with the matter told Reuters.

PARIS (Reuters) - French food giant Danone (>> DANONE), maker of Activia yoghurt and Evian water, has decided it wants to pursue a takeover of U.S. infant formula maker Mead Johnson Nutrition Group (>> Mead Johnson Nutrition CO), sources familiar with the matter told Reuters.

"Danone has done its internal strategic review and decided that Mead Johnson is its preferred acquisition," one of the sources said, speaking on condition of anonymity because the matter is private.

Paris-based Danone has been grappling with falling earnings, and investors have begun to question whether the company can thrive in its current form as it competes with much-larger rivals Nestle (>> Nestle SA) and Unilever (>> Unilever plc).

The company is also trying to reduce its dependence on slow-growth Europe, recently doing deals in emerging markets like China and Africa.

With regard to Mead Johnson, the sources did not say whether Danone had made any approach to Mead Johnson or hired any advisors. Danone and Mead Johnson declined to comment.

Shares in the U.S. firm were up 9.5 percent at $99.91 in afternoon trade in New York.

JPMorgan analysts estimated that Mead Johnson would not sell for less than 20 times operating earnings, or $120 per share, based on the multiple of 20 times that Nestle paid for Pfizer's (>> Pfizer Inc.) infant formula business in 2012 and the 22 times that Danone paid for Numico's baby food business in 2007.

Those multiples suggest a deal value of $24 billion to $26 billion, based on the number of Mead Johnson shares outstanding as of July 17.

Any deal for Mead Johnson, which was spun off from drugmaker Bristol-Myers Squibb (>> Bristol-Myers Squibb Co) in 2009, would use cash and shares and would not be driven by tax issues, said a second source.

Analysts have long said that Mead Johnson, the maker of Enfamil baby formula, would be a logical but ambitious move for Danone, helping it grow in Latin America and Asia.

Many have speculated that Danone might sell an asset before buying one, repeating the pattern from 2007, when it bid 12.3 billion euros for Numico less than a week after announcing the 5.3 billion euro sale of its biscuit business to Kraft.

Reuters first reported in February that Danone was looking to sell its medical nutrition business, worth between 4 billion euros and 7 billion euros ($5-9 billion) depending on how much they sell, according to analysts. [ID:nL5N0LH4DT]

German healthcare group Fresenius (>> Fresenius SE & Co KGaA), together with private equity funds PAI and Permira, are the last bidders left in a race that had included Hospira (>> Hospira, Inc.) and Nestle, several other sources familiar with the matter said. [ID:nL6N0SC3ZN]

"The deal is very complex and is unlikely to close before March next year and is conditional on Danone making a move for Mead Johnson," one of them said.

"Danone needs to sell something before (bidding for Mead Johnson) and medical nutrition will likely to take some time," said a third source familiar with the matter.

Danone has always declined to comment on speculation it was planning to sell its medical nutrition business. CFO Pierre Andre Terisse again declined to discuss the issue on a call with analysts on Oct. 15.

RESHUFFLING

On Sept 2, Danone said its chairman and chief executive, Franck Riboud, would split his role after 18 years running the company.

Riboud, 58, who took over from his late father, Antoine Riboud, in 1996, remains chairman to focus on the company's long-term strategy while Emmanuel Faber, 50, the chief operating officer, became CEO on Oct. 1.

Analysts speculated that the move was partly a sign that top management felt a threat to Danone's independence.

In 2005 the French government deemed dairy a "protected" industry amid rumours that PepsiCo (>> PepsiCo, Inc.) was preparing to make a bid for Danone.

More recently, Danone's lacklustre performance has attracted criticism, notably from U.S. activist investor Nelson Peltz, who suggested in 2012 that Danone could benefit from a leaner cost structure.

The company makes 55 percent of revenue from dairy products, a sector hit by a spike in milk prices and weak consumer spending in austerity-hit Europe. Its water business makes up 18.5 percent, while its baby food business, which had been hit by a safety scare in China, makes up 20 percent.

Medical nutrition, which sells specialised products to feed the sick, makes up around 6.5 percent of sales.

The global retail market for formula, including that for infants and toddlers, is estimated at $44.8 billion this year, according to Euromonitor International, which expects it to top $84 billion in five years. More than half of the sector's sales are in Asia, growing more than 16 percent a year.

Nestle is the global leader for formula with a 22 percent share, Mead Johnson is second with 13.6 percent and Danone is third with 11.8 percent, according to Euromonitor.

($1 = 0.7833 euro)

(Writing by Anjuli Davies and Martinne Geller in London; Editing by Greg Mahlich and David Evans)

By Sophie Sassard

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -1.63% 43.33 Delayed Quote.-15.26%
CLASS III MILK FUTURES (DC) - CMG (ELECTRONIC)/C1 -0.11% 17.4 End-of-day quote.25.96%
CLASS IV MILK?FUTURES (GDK) - CMG (ELECTRONIC)/C1 -0.06% 16.9 End-of-day quote.11.85%
DANONE -0.58% 75.3 Real-time Quote.22.42%
DRY WHEY?FUTURES (DY) - CMG (ELECTRONIC)/C1 0.91% 36.2 End-of-day quote.-23.67%
FRESENIUS SE & CO. KGAA -0.65% 45.03 Delayed Quote.6.25%
NESTLÉ -1.06% 102.6 Delayed Quote.29.95%
NONFAT DRY MILK FUTURES (GNF) - CMG (ELECTRONIC)/C1 0.12% 103.9 End-of-day quote.14.35%
UNILEVER PLC -1.07% 5011 Delayed Quote.21.97%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DANONE
07/10CDP Launches Global Environmental Index With Goldman Sachs
DJ
07/08Nestle Waters teams up with Ocean Legacy for plastic waste cleanup
RE
06/13Danone CFO says China's baby formula plan 'not a surprise'
RE
06/03DANONE : launches its first global Employee Share Subscription Plan
PU
06/03DANONE : Danone launches its first global Employee Share Subscription Plan
AQ
05/08DANONE : Marking 100 years since the creation of its first yogurt, Danone opens ..
GL
05/08Nestle, rivals vie for big baby formula prize in China's smaller cities
RE
05/07DANONE : Ex-dividend day for final dividend
FA
04/25DANONE : 2019 Danone Shareholders' Meeting
PU
04/25DANONE : 2019 Danone Shareholders' Meeting: approval of all resolutions
AQ
More news
Financials (EUR)
Sales 2019 25 321 M
EBIT 2019 3 847 M
Net income 2019 2 387 M
Debt 2019 11 990 M
Yield 2019 2,73%
P/E ratio 2019 20,2x
P/E ratio 2020 18,2x
EV / Sales2019 2,40x
EV / Sales2020 2,28x
Capitalization 48 777 M
Chart DANONE
Duration : Period :
Danone Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DANONE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 78,92  €
Last Close Price 75,30  €
Spread / Highest target 20,8%
Spread / Average Target 4,81%
Spread / Lowest Target -13,7%
EPS Revisions
Managers
NameTitle
Emmanuel Faber Chairman & Chief Executive Officer
Cécile Cabanis CFO, Executive VP-Strategy & Information Systems
Benoît Potier Independent Director
Isabelle Seillier Non-Independent Director
Jean-Michel Sévérino Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DANONE22.42%54 732
NESTLÉ29.95%301 591
MONDELEZ INTERNATIONAL37.12%79 066
THE KRAFT HEINZ COMPANY-26.72%38 477
GENERAL MILLS36.83%31 765
THE HERSHEY COMPANY35.45%30 314